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Key Clinical Message
Our case report discusses the usefulness of administering romiplostim as a sec-
ond-line treatment before splenectomy in a cirrhotic patient with immune
thrombocytopenia who developed corticosteroid-induced Cushing’s syndrome.
Corticosteroids were tapered and consequently withdrawn. The patient made a
full recovery postsplenectomy.
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Introduction
This case report describes the clinical case of a patient
with chronic liver disease (CLD) who suffered chronic
immune thrombocytopenia (ITP), for more than one year
which defines a chronic evolution.
Chronic ITP is an acquired immune disorder character-
ized by isolated thrombocytopenia. The diagnosis of ITP
is established by the exclusion of other causes of low pla-
telets count such as bone marrow failure, especially malig-
nancy, infections, alcohol excess, or drug induced.
Severe clinical manifestations may be observed associ-
ated with ITP. Patients can suffer: gastrointestinal bleed-
ing, extensive skin, mucosal, or intracranial hemorrhage.
On physical examination, you can find splenomegaly and
hepatomegaly. In our patient, these findings were attribu-
ted initially to his concomitant chronic liver disease. Our
patient had compensated cirrhosis, Child A status,
according to the prognostic classification of cirrhosis. His
analytical parameters had only mild abnormalities severe;
however, severe thrombocytopenia was observed which is
not usually secondary to portal hypertension.
The patient received the first-line treatments proposed
by the clinical guidelines with intravenous immunoglobu-
lins and prednisone. Despite showing no signs of
improvement, the administration of prednisone was con-
tinued in the long term and the patient developed iatro-
genic Cushing’s syndrome. Because the patient failed to
respond to first-line treatment, a bone marrow examina-
tion was carried out. This test is usually not performed as
an initial investigation if the history and clinical examina-
tion fit with the diagnosis of ITP.
The second line of recommended treatment is to per-
form a splenectomy, but the deteriorated clinical condi-
tion and comorbidities of our patient precluded it. At
present, the recommendation for a second line of treat-
ment is the administration of a thrombopoietin receptor
agonists (TPO), romiplostim, or eltrombopag. In our
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patient, romiplostim was administered while tapering and
suspending prednisone. When the patient was stabilized,
splenectomy could be performed with the expected nor-
malization of clinical situation and platelet count.
Splenectomy is one of the second-line treatments for
adults with ITP.
Case Presentation
In 2002, the patient, a 64-year-old male, presented at the
emergency room with severe thrombocytopenia and a
self-limited intestinal hemorrhage of unknown origin and
was diagnosed with chronic liver disease, Child A sta-
tus. The cause of cirrhosis was attributed to alcohol
consumption in the past. A bone marrow examination
was performed and showed normal megakaryocytes, and
as a result, hematological diseases were excluded.
Thrombocytopenia persisted and was considered sec-
ondary to hypersplenism. The initial laboratory values
are shown in Table 1, highlighting the severity of
thrombocytopenia.
During the period 2005–2009, he suffered from
repeated hemorrhages. Hence, he was treated with the
first-line therapy which is IV IgG and prednisone. During
these years, he needed emergency treatments and was
hospitalized on several occasions. In spite of standard
therapies, hemorrhages persisted but he did not develop
liver decompensation.
In June 2009, he was hospitalized for ecchymoses, rectal
bleeding, and severe thrombocytopenia requiring blood
transfusions, IV IgG, and high doses of prednisone
(1 mg per kilogram of body weight per day). A bone
marrow exam was repeated, and no abnormalities were
detected.
In August, October, and November 2009, he needed to
be re-hospitalized for epistaxis and intestinal hemorrhage
and his platelet count was 1.000–3.000 cells/mm3. Long-
term high doses of prednisone, 100 mg/day, were adminis-
tered from June 2009 to April 2010. Hemorrhages were
clinically stabilized, but the patient’s clinical situation dete-
riorated.
In November 2009, he was referred to our clinic for
evaluation of his chronic liver disease. He had developed
iatrogenic Cushing syndrome with cardiovascular compli-
cations (shortness of breath, swollen extremities, weight
increase). Table 2 shows the values of the patient’s vital
signs. General and specific analysis and abdominal dop-
pler ultrasound were performed. Symptomatic treatment
was established while tapering prednisone.
In March 2010, he started romiplostim treatment as a
bridge for splenectomy. Taking into account his chronic
liver disease and risk of vascular thrombosis, the target
platelet count range was an average of 50,000–
90,000 cells/mm3. Efficacy and safety were assessed
weekly, during each visit. Figure 1 shows the platelet
count during this period.
In December 2010, prednisone was totally stopped and
this allowed the patient to be considered for splenectomy.
He was given an antipneumoccocal, meningococcal, and
hemophilus influenzae vaccinations and underwent
Table 1. Initial laboratory values.
Laboratory tests Value Normal range
White blood cell count (cells/mm3) 3 3.9–10
Mean corpuscular volume (fL) 91 81–96
Platelets (cells/mm3) 13 135–333
Hemoglobin level (g/L) 120 126–166
Bone marrow examination Showed no disorders Not applicable
International normalized ratio (INR) 1.2 0.8–1.2
Creatinine (lmol/L) 80 <111
Aspartate amino transferase (lKat/L) 0.51 <0.50
Alanine amino transferase (lKat/L) 0.38 <0.73
Alkaline phosphatase (lKat/L) 1.3 <1.5
Total bilirubin (mmol/L) 19 <18
Gamma-glutamyl transpeptidase (lKat/L) 1.7 <1.11
Albumin (g/L) 38 33–50
Glucose (mmol/L) 5.6 4.1–6.9
Cobalamin/Folate (pmol/L/pmol/L) 291.9/6.8 ≥122/>45.4
Lactate dehydrogenase (LDH) lKat/L 6.3 <3.4
Standard urinalysis All within normal limits Not applicable
Hepatitis B virus and hepatitis C virus Ab Negative Negative
Hepatitis autoimmune Ab (antinuclear, antimitochondrial, antismooth muscle, and anti-KLM) Negative Negative
lmol/L, micromoles per Liter; lKat/L, microkat per Liter; mmol/L, millimoles per Liter; pmol/L, picomol per Liter; Ab, antibodies.
Bold values means severity of low platelets count.
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computed axial tomography (CAT) (Fig. 2) and abdomi-
nal ultrasound test. In addition, a nuclear medicine study
was carried out of the liver–spleen image with 99 mTc-
labeled colloid, confirming enlarged spleen and a reduced
platelet half-life with a pattern of increased splenic
destruction.
In May 2011, open laparotomy with splenectomy was
performed with a liver biopsy specimen obtained preoper-
atively, which showed advanced fibrosis without steatosis
or other features. After the surgery, the patient showed
full recovery.
Today, after 5 years of follow-up, the patient only
requires vitamin supplements and standard ambulatory
checkups every 6 months. His liver function remains
stable, and platelet count is maintained at normal range.
Discussion
We present the clinical case of a patient with chronic liver
disease (CLD) and severe thrombocytopenia [1] who after
9 years of suffering repeated hemorrhages developed
iatrogenic Cushing syndrome secondary to high doses of
prednisone. He received romiplostim as a second line of
immune thrombocytopenia (ITP) therapy [2] for a period
of nine months while prednisone was tapered before a
splenectomy could be indicated.
In CLD patients, thrombocytopenia is a common clini-
cal problem associated with hypersplenism but ITP disor-
der is rarely encountered [1].
Thrombocytopenia in liver cirrhosis is typically less sev-
ere than that found in ITP, which may be secondary to
hematological diseases, chemotherapy, some drugs, hep-
atitis C-related, and myelodysplastic syndromes [3]. In
our patient, secondary causes of ITP were ruled out and
the diagnosis of ITP was well established.
Table 2. Patient’s vital sign values pretreatment with romiplostim.
Blood pressure 180/90
Pulse (bpm) 67
Weight (Kg)/Height (cm) 102/168










Figure 1. Platelet count level over time and correlation with medical treatment and splenectomy.
Figure 2. Abdominal CT scan lobular liver, suggesting cirrhosis
without nparenchimal, biliary or vascular lesions, normal portal vein
and enlarged spleen (19 cm.). Kidney of normal size and morphology.
No retroperitoneal or lymphadenopathy and no free peritoneal fluid
were observed.
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Treatment of ITP in our patient was a challenge due to
the risks associated with liver disease and also to the
Cushing Syndrome and cardiovascular complications
observed [4]. Therefore, our major concern while decreas-
ing the doses of prednisone was how to treat the underly-
ing thrombocytopenia and hypercortisolism with heart
failure and hypertension avoiding steroid withdrawal syn-
drome.
Nowadays, clinical guidelines for ITP in newly diag-
nosed adults recommend rituximab, thrombopoietin
receptor agonist (TPO), TPO-RA (romiplostim or eltrom-
bopag), or splenectomy for patients who are unresponsive
or who have relapsed after initial IV IgG and corticos-
teroid therapies. Splenectomy is one of the second-line
treatment for adults with ITP. [5, 6].
It is important to note that in case of resistance to the
first-line therapy, as was observed in our patient, other
options such as splenectomy should be considered. How-
ever, in patients with CLD, portal hypertension and
thrombocytopenia represent obstacles to surgical proce-
dures.
Splenectomy has been the standard second-line treat-
ment for adults with ITP and remains a good option [7].
Due to the deleterious effects of long-term use of high
doses of prednisone, our patient’s clinical condition was
severely deteriorated, and this was a cause for deterring
and contraindicating the splenectomy that should have
been performed once clinicians realized that the patient
was nonresponding to the first-line treatment. Doctors
may be hesitant to indicate splenectomy as some adults
improve over time or spontaneously or as a result of
medical treatment.
Avoiding or delaying splenectomy is usual and is evi-
denced by a decrease in the rate of splenectomies per-
formed in recent years.
However, the majority of groups accept splenectomy as
a second-line treatment after failure of steroids and in the
absence of contraindication. Failure is defined by a
remaining platelet count of less than 10,000–30,000, active
bleeding, or high steroid requirement [8].
Although romiplostim had not been tested specifically
in chronic liver disease, after examining the pros and
cons, it was indicated.
Many recent clinical case reports have shown a possi-
ble role of romiplostim in the preparation preliver
transplant or prior for invasive therapeutic procedure
[9–11].
Thrombocytopenia associated with advanced liver dis-
ease has a multifactorial origin. Usually a combination of
causes can be implicated, producing an imbalance
between production and destruction of platelets. A reduc-
tion of synthesis of TPO, which is produced exclusively
by the liver, has been observed and also an increased
splenic sequestration as a consequence of portal hyperten-
sion [12].
The etiology of thrombocytopenia in our patient was
attributed to hypersplenism, although since the beginning
a component of ITP could not be discarded. Despite per-
forming a scintigraphic evaluation which confirmed the
platelet sequestration and destruction in the spleen, these
results are not totally predictive [13]. Complications
related to romiplostim treatment have been described:
thrombotic events related to an elevated number of plate-
lets, lack of response due to fibrous tissue deposition in
bone marrow, worsening thrombocytopenia due to a
rebound effect etc. [14].
It is worthwhile presenting this patient because not
only did treatment with romiplostim improves platelet
count but it also enabled a clinical improvement, thus
allowing him to be splenectomised [15].
Due to the presence of iatrogenic Cushing syndrome
with cardiovascular complications in our patient, there
were some concerns regarding the impact of romiplostim
on his management. Nevertheless, romiplostim was well
tolerated. However, the possibility of severe complica-
tions, especially in patients with decompensated cirrhosis,
should be considered.
The outcome after splenectomy was uneventful. Cirrho-
sis was not decompensated during the treatment period,
and a Child A status was maintained indicating a rela-
tively good liver function and a good prognosis for sur-
gery.
Conclusion
This case report emphasizes the hazards of long-term
administration of prednisone, which in our patient
resulted in Cushing’s syndrome, and shows how romi-
plostim was used to maintain a safe platelet count while
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